Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT03033914 |
| Title | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Memorial Sloan Kettering Cancer Center |
| Indications | |
| Therapies |
Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Bleomycin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine |
| Age Groups: | adult | senior |
| Covered Countries | USA | CAN |